Regorafenib and Nivolumab Simultaneous Combination Therapy for Advanced and Metastatic Solid Tumors: Phase I Clinical Trial
Latest Information Update: 15 Jun 2022
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer; Gastric cancer; Liver cancer; Solid tumours
- Focus Adverse reactions
- Acronyms REGONIVO
- 09 Jun 2022 Results of updated efficacy outcomes from REGONIVO plus LENPEM cohort published in the Clinical Cancer Research
- 23 Apr 2021 Status changed from active, no longer recruiting to completed.
- 09 Sep 2020 Planned End Date changed from 31 Jul 2022 to 30 Apr 2022.